Merck (MRK) announced FDA has extended the PDUFA date of the supplemental biologics license application for VAXNEUVANCE in infants and children to July 1, 2022. Merck said the FDA requested additional analyses of data from the pediatric studies, which it has submitted to the FDA.
"We are confident in the strength of the data from our pediatric studies with VAXNEUVANCE and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible," said Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.